Hypertension in hemodialysis patients is multifactorial and requires comprehensive management including volume control and appropriate antihypertensive pharmacotherapy.
Answers are grounded in this paper and cite their sources.
May inform volume and pharmacotherapy strategies in hemodialysis hypertension; leaves open optimal targets and sequences from prospective trials.
Chronic Kidney disease (CKD) patients, particularly those with end stage renal disease (ESRD), are at much risk of cardiovascular disease than the general population. Cardiovascular disease is by far the leading cause of and mortality in dyalisis patients, accounting for almost 40% of hospitalizations and almost 50% of deaths. is the single most important factor for the development of cardio and cerebrovascular complications. The -pathogenesis of hypertension in dialysis patients is multifactorial, sodium excess and extracellular volume expansion the major factor in the development of hypertension, however there are other pathogenetic factors that should be considered, such as renin-angiotensin system hyperactivity, increased sympatic activity, altered endothelial cell function, hyperparathiroidism, and oxidative stress. The most important risk factors are anemia, hypoalbuminemia, chronic inflammation, prothrombotic factors, hyperomocisteinemia, vascular calcification and the traditional factors for cardiovascular risk (age, male gender, diabetes mellitus, dyslipidemia, smoke, physical inactivity, alcohol abuse). blood pressure is frequent also in children on long term dialysis therapy. Data suggest that uremic factors or factors related to renal replacement therapy may be implicated in the pathogenesis of heart disease in adults and pediatric patients, because cardiovascular survival improves after transplantation. management of hypertension requires lifestyle modifications and control of volume status, with dietary salt and fluid in combination with reduction of dialysate sodium concentration or with programmed “variable–sodium” dialysis. relationship between interdialytic weight and blood pressure is incompletely characterized; the dry weight (DW) relies on the progressive reduction of the postdialysis body weight until blood pressure is normalized. There are non clinical methods for evaluation DW such as measure the inferior vena cava diameter whit ultrasound, measure volume (BV) whit radiolabeled albumin and calculating post-hemodialysis BV from the change in hematocrit. may exist a lag time of several weeks between the normalization of the extracellular volume and blood pressure. It is related to the correction of the hemodinamic consequences of the extracellular volume overload. other problems to limit the possibility of correcting adequately volume expansion with dialysis are the use of antihypertensive drugs and the aggressive ultrafiltration required by short dialysis times. A possible treatment option for these may be increase time hemodialysis with slow, long hemodialysis; short, daily hemodialysis or nocturnal hemodialysis. classes of antihypertensive drugs can be used in dialysis patients, except the diuretics because inefficacy. Angiotensinconverting enzyme (ACE) and Angiotensin T1 receptor antagonist (AT1RA) appear to have the greatest ability to reduce ventricular mass.
No takes yet. Share an insight, caveat, or question.
Cianci et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: